Schubert Jonckheer & Kolbe LLP advises Aquestive Therapeutics, Inc. (Nasdaq: AQST) investors that the firm is investigating potential legal claims arising from alleged false and misleading statements about the company’s drug candidate Anaphylm. Current shareholders are encouraged to contact the firm.
On January 9, 2026, Aquestive announced that the FDA had identified deficiencies in its New Drug Application for Anaphylm that precluded discussions of labeling and post-marketing commitments. Following this news, Aquestive’s stock price declined 37%.
According to a securities class action complaint, between June 2025 and January 2026, Aquestive misled investors about the prospects for FDA approval of Anaphylm, including by representing that approval remained on track for the January 31, 2026 target action date.
We are investigating potential wrongdoing by Aquestive’s directors and officers in connection with these allegations.
If you own Aquestive stock, you may have legal options. To obtain additional information about your legal rights, please fill out the form below to learn more.
Schubert Jonckheer & Kolbe LLP advises Aquestive Therapeutics, Inc. (Nasdaq: AQST) investors that the firm is investigating potential legal claims arising from alleged false and misleading sta...